Dating shushu ua


14-Oct-2019 02:35

Although the blood vessels to dilate and increase the pain and migraine-related symptoms, but this type of neurovascular events currently considered to be the result of the disease rather than the cause.

[0015] The invention disclosed herein relates to anti-CGRP antagonist antibodies and methods of administration of anti-CGRP antibody for treating or preventing vasomotor symptoms antagonist, said vasomotor symptoms such as headache, if aura or migraine without aura, hemiplegic migraine, cluster headache, migraine, neuralgia, chronic headaches, tension headaches, and headaches resulting from other medical conditions (such as infection caused by a tumor or increased intracranial pressure).

[0016] In one aspect, the present invention provides a method for treating or preventing at least one vasomotor symptom in an individual, said method comprising administering an effective amount of an anti-CGRP antagonist antibody.

[0017] In one aspect, the present invention provides a method for treating or preventing headache (e.g., migraine and cluster headache) in an individual, said method comprising administering an effective amount of an anti-CGRP antagonist antibody.

dihydroergotamine base Corning, dihydroergotamine Ting, dihydroergotamine ergocryptine and dihydroergotamine mesylate (DHE 45) ).

Examples of NSAIDs which may be used in combination with anti-CGRP antibodies [0021] include naproxen, flurbiprofen, ketoprofen, oxaprozin, etodolac, indomethacin, ketorolac, nabumetone , that dense Maifei acid (mefanamic acid), and piroxicam.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. 13 = 453-464 (2001)) "So far, for the flushing of the most effective therapy is based on hormone therapy, said hormones include estrogens and / or some progestins.

CGRP is a neurotransmitter in the central nervous system, and has been shown to be effective in the outer peripheral vasodilator, CGRP-containing neurons in close connection with the outer periphery of the blood vessel. Murphy et al, 3 sup rd Int ' I Symposium on Recent...[0018] another aspect, the present invention provides for improvement in an individual, control, reduction of headache (e.g., migraine and cluster headache) the onset or development or progression of headache delay, said method comprising administering an effective amount of the anti-CGRP antagonist antibody.